Billiontoone Inc Quick Ratio (BLLN) starting from the second quarter 2026 to second quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Billiontoone Inc   (NASDAQ: BLLN)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

Billiontoone Inc 's Quick Ratio

BLLN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Billiontoone Inc 's Cash & cash equivalent grew by 2.08 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Billiontoone Inc 's Quick Ratio to 9.85, above Billiontoone Inc average Quick Ratio.

Within Medical Laboratories industry 4 other companies have achieved higher Quick Ratio than Billiontoone Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 427 to 468.

Explain Quick Ratio?
How much Cash & cash equivalents BLLN´s has?
What are BLLN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BLLN Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Dec 31 2024)
Q2
Y / Y Current Liabilities Change 161.72 % - - - -
Y / Y Cash & cash equivalent Change 186.52 % - - - -
Quick Ratio MRQ 9.85 9.4 10.34 4.78 8.99
BLLN's Total Ranking # 468 # 427 # 294 # 0 #
Seq. Current Liabilities Change -2.51 % 19.18 % 17.6 % 91.55 % -
Seq. Cash & cash equivalent Change 2.08 % 8.36 % 154.15 % 1.92 % -



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Medical Laboratories Industry # 5
Healthcare Sector # 165
Overall Market # 468


Quick Ratio Statistics
High Average Low
10.34 8.67 4.78
(Dec 31 2025)   (Sep 30 2025)




Financial Statements
Billiontoone Inc 's Current Liabilities $ 56 Millions Visit BLLN's Balance sheet
Billiontoone Inc 's Cash & cash equivalent $ 549 Millions Visit BLLN's Balance sheet
Source of BLLN's Sales Visit BLLN's Sales by Geography


Cumulative Billiontoone Inc 's Quick Ratio

BLLN's Quick Ratio for the trailling 12 Months

BLLN Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 846.99 % - - - -
Y / Y Cash & cash equivalent TTM Growth 828.16 % - - - -
Quick Ratio TTM 8.81 8.49 8.02 6.23 8.99
Total Ranking TTM # # # # #
Seq. Current Liabilities TTM Growth 20.59 % 51.95 % 77.26 % 191.55 % -
Seq. Cash & cash equivalent TTM Growth 25.15 % 60.89 % 128.28 % 101.92 % -

Quick ratio ranking by company, industry and sector >> Back to BLLN Financial Strength Comparisons >> Go to Compare BLLN Quick Ratio to its Competitors

On the trailing twelve months basis BLLN Cash & cash equivalent more than doubled by 186.52 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Billiontoone Inc 's Quick Ratio to 8.81, above BLLN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 4 other companies have achieved higher Quick Ratio than Billiontoone Inc . While overall ranking is unchanged compared to the previous 12 months at no. 0.

Explain Quick Ratio?
How much Cash & cash equivalents BLLN´s has?
What are BLLN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Medical Laboratories Industry # 5
Healthcare Sector # 165
Within the Market # 468


trailing twelve months Quick Ratio Statistics
High Average Low
10.34 8.67 4.78
(Dec 31 2025)   (Sep 30 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Medical Laboratories Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Aclarion Inc   15.50 $ 16.285  Millions$ 1.051  Millions
Miragen Therapeutics Inc   12.67 $ 981.530  Millions$ 77.484  Millions
Maxcyte inc   10.68 $ 105.690  Millions$ 9.895  Millions
Grail Inc   10.29 $ 859.755  Millions$ 83.542  Millions
Absci Corp  10.12 $ 201.142  Millions$ 19.878  Millions
Billiontoone Inc   9.85 $ 548.628  Millions$ 55.725  Millions
Celcuity Inc   8.68 $ 754.000  Millions$ 86.873  Millions
Veracyte Inc   7.76 $ 487.046  Millions$ 62.736  Millions
Personalis Inc   6.00 $ 278.411  Millions$ 46.385  Millions
Castle Biosciences Inc   4.72 $ 266.805  Millions$ 56.509  Millions
Bionexus Gene Lab Corp   4.33 $ 3.522  Millions$ 0.813  Millions
Caredx Inc   3.99 $ 373.636  Millions$ 93.698  Millions
Omniab Inc   3.78 $ 51.995  Millions$ 13.758  Millions
Fulgent Genetics Inc   3.58 $ 257.032  Millions$ 71.756  Millions
Guardant Health Inc   3.11 $ 1,053.469  Millions$ 338.962  Millions
Butterfly Network Inc   2.13 $ 124.659  Millions$ 58.603  Millions
Natera Inc   1.97 $ 1,091.502  Millions$ 553.200  Millions

Date modified: 2026-09-08T15:11:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.